Entero Therapeutics (ENTO) Competitors $4.35 +0.01 (+0.23%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.20 -0.15 (-3.33%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. MAAQ, KLTO, RENB, TENX, DARE, CVKD, KZR, LEXX, RNTX, and XCURShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Mana Capital Acquisition (MAAQ), Klotho Neurosciences (KLTO), Lunai Bioworks (RENB), Tenax Therapeutics (TENX), Dare Bioscience (DARE), Cadrenal Therapeutics (CVKD), Kezar Life Sciences (KZR), Lexaria Bioscience (LEXX), Rein Therapeutics (RNTX), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors Mana Capital Acquisition Klotho Neurosciences Lunai Bioworks Tenax Therapeutics Dare Bioscience Cadrenal Therapeutics Kezar Life Sciences Lexaria Bioscience Rein Therapeutics Exicure Mana Capital Acquisition (NASDAQ:MAAQ) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Which has preferable valuation and earnings, MAAQ or ENTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/AEntero TherapeuticsN/AN/A-$18.06MN/AN/A Do insiders & institutionals believe in MAAQ or ENTO? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is MAAQ or ENTO more profitable? Mana Capital Acquisition's return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Entero Therapeutics N/A -1,063.82%-17.94% Does the media favor MAAQ or ENTO? In the previous week, Entero Therapeutics had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat Entero Therapeutics' score of -0.33 indicating that Mana Capital Acquisition is being referred to more favorably in the media. Company Overall Sentiment Mana Capital Acquisition Neutral Entero Therapeutics Neutral Do analysts prefer MAAQ or ENTO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryMana Capital Acquisition beats Entero Therapeutics on 4 of the 7 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.91M$3.36B$6.14B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E RatioN/A22.1478.0526.70Price / SalesN/A458.33605.13131.81Price / CashN/A47.8637.9061.31Price / Book-1.789.9312.556.55Net Income-$18.06M-$52.80M$3.31B$277.50M7 Day Performance-8.42%5.22%4.28%2.41%1 Month Performance64.15%13.01%7.85%9.30%1 Year Performance141.79%25.18%71.37%31.22% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$4.35+0.2%N/A+316.2%$6.91MN/A0.009Analyst UpgradeShort Interest ↑Gap DownMAAQMana Capital AcquisitionN/A$3.91-2.0%N/A+1,747.8%$31.77MN/A0.001KLTOKlotho Neurosciences0.6403 of 5 stars$0.51-2.8%N/AN/A$31.00MN/A-1.12N/AGap UpRENBLunai Bioworks0.5973 of 5 stars$0.17+5.6%N/A-69.3%$29.71MN/A-0.2220Stock SplitGap DownHigh Trading VolumeTENXTenax Therapeutics1.8787 of 5 stars$6.50-0.5%$18.00+176.9%+128.7%$29.66MN/A-7.079News CoverageDAREDare Bioscience1.2366 of 5 stars$2.14+3.9%$10.00+367.3%-31.4%$28.85M-$17.70K-1.0030CVKDCadrenal Therapeutics2.4861 of 5 stars$13.78+0.7%$32.00+132.2%+24.4%$28.21MN/A-1.554KZRKezar Life Sciences2.7941 of 5 stars$3.80-2.3%$9.00+136.8%-52.5%$27.82M$7M-0.3960High Trading VolumeLEXXLexaria Bioscience2.5988 of 5 stars$1.42+8.4%$4.00+181.7%-73.5%$27.78M$460K-2.127RNTXRein Therapeutics3.0923 of 5 stars$1.19+6.3%$10.00+740.3%N/A$27.74MN/A-0.449Gap UpHigh Trading VolumeXCURExicure1.1754 of 5 stars$4.25+21.1%N/A+50.5%$26.86M$500K-1.1050 Related Companies and Tools Related Companies Mana Capital Acquisition Competitors Klotho Neurosciences Competitors Lunai Bioworks Competitors Tenax Therapeutics Competitors Dare Bioscience Competitors Cadrenal Therapeutics Competitors Kezar Life Sciences Competitors Lexaria Bioscience Competitors Rein Therapeutics Competitors Exicure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
